Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Jazz Pharmaceuticals (JAZZ) Price Forecast: Multi-Year Base Signals Breakout Potential
05:28pm, Thursday, 12'th Mar 2026
Shares of Jazz Pharmaceuticals plc are consolidating below record highs after a bull-flag breakout, with tightening price action suggesting a potential breakout from a multi-year base.
Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
12:12pm, Thursday, 12'th Mar 2026
Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Crossmark Global Holdings Inc. Sells 10,433 Shares of Jazz Pharmaceuticals PLC $JAZZ
03:46am, Thursday, 12'th Mar 2026
Crossmark Global Holdings Inc. lessened its stake in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 74.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securiti
JAZZ or ACAD: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 09'th Mar 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Acadia Pharmaceuticals (ACAD). But which of these two stocks o
Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
03:52pm, Tuesday, 03'rd Mar 2026
Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
10:16am, Monday, 02'nd Mar 2026
Examine Jazz's (JAZZ) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock?
10:55am, Friday, 27'th Feb 2026
Jazz Pharmaceuticals JAZZ has reached a milestone that most conventional cannabis players are yet to achieve — generating sustained, billion-dollar revenues from a cannabis product.
Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts' earnings estimat
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook
08:19am, Thursday, 26'th Feb 2026
Jazz Pharmaceuticals is positioned for long-term value creation, with a relief rally following Q4 2025 results and 2026 outlook for the oxybate business. Jazz expects Xywav revenues to be flat or up m
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
12:01pm, Wednesday, 25'th Feb 2026
Jazz Pharmaceuticals beats Q4 earnings and revenue estimates as neuroscience and oncology sales climb, sending shares up 5% in after hours.
Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript
12:57am, Wednesday, 25'th Feb 2026
Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript
Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
09:00pm, Tuesday, 24'th Feb 2026
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street
Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates
08:31pm, Tuesday, 24'th Feb 2026
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.64 per share, beating the Zacks Consensus Estimate of $6.62 per share. This compares to earnings of $6.6 per share a year ago.
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
04:05pm, Tuesday, 24'th Feb 2026
– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 – – Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA – – Xy
What Analyst Projections for Key Metrics Reveal About Jazz (JAZZ) Q4 Earnings
10:16am, Thursday, 19'th Feb 2026
Evaluate the expected performance of Jazz (JAZZ) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo
